Despite advances in screening, many cases of cancer go undetected until they have progressed to the point where treatment options are limited. The Molecular Imaging Pipeline at UHN aims to develop and translate new molecular imaging techniques for detecting and diagnosing cancer earlier and more accurately. By using specialized probes that interact with a patient’s biology, molecular imaging can further provide insight into disease processes and enable treatments to be precisely targeted and tailored to individual patients. > Read More

Human factors is a discipline that focuses on interactions between human beings and systems to improve efficiency, creativity, productivity, safety and minimization of errors. The inception of the Healthcare Human Factors (HHF) department at UHN was rooted in the necessity to assess the design and usability of technology being procured to fit the needs of clinicians, technicians and other stakeholders. > Read More

The growing demand for accelerating the benefits of cell and gene therapies led to the establishment of The Centre for Cell and Vector Production (CCVP) in partnership with the Centre for Commercialization of Regenerative Medicine (CCRM). CCVP features cutting-edge equipment and world-class Good Manufacturing Practice (GMP) requirements, including those set by U.S. Food and Drug Administration, Health Canada and the European Medicines Agency. > Read More

We are excited to share with the UHN community the rebranding of the UHN Biobank to the Princess Margaret Cancer Biobank (PMCB).

The program will continue to operate under the leadership of Dr. Neil Fleshner (Medical Director), Heidi Wagner (Head of Operations) and Dr. Hal Berman (Scientific Advisor). The program will also continue to provide top-quality biobanking and digital pathology services in efforts to fuel research and positively impact clinical managing and patient outcomes.

To find out more about the program please visit PMCB’s brand new website https://princessmargaretcancerbiobank.com/ .